Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2006-05-16
2006-05-16
Qian, Celian (Department: 1636)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S320100
Reexamination Certificate
active
07045508
ABSTRACT:
Disclosed are methods for transient co-administration of rapamycin together with a gene therapy vector encoding a transgene. The present invention is directed to inhibiting the immune response of a host to the administered gene therapy vector and encoded transgene product, thus allowing persistent transgene expression and repeated administration of the gene therapy product to the host. The present invention is also of relevance in genetic disease patients that mount immune responses to protein replacement therapies in which case the present invention provides for transient co-administration of rapamycin together with protein replacement therapy. In a further aspect of the invention, co-administration of rapamycin could inhibit a secondary immune response in a host that has been pre-immunized with the gene therapy vector or pre-immunized with the protein product encoded by the transgene.
REFERENCES:
patent: WO 96/12406 (1996-05-01), None
patent: WO 97/39776 (1997-10-01), None
patent: WO 00/63369 (2000-10-01), None
Verma, 1997, Science, vol. 389, p. 239-242.
Nishikawa et al. (2001, Human Gene Therapy, vol. 12, pp. 861-870).
Anderson (1998, Nature, vol. 392, pp. 25-30).
PCT Search Report, filed Jul. 25, 2001, Genzyme.
Dai, Yifan et al., Cellular and Humoral Immune Responses To Adenoviral Vectors Containing Factor IX Gene: Tolerization of Factor IX and Vector Antigens Allows for Long-Term Expression, Proc. Natl. Acad. Sci. USA, vol. 92, pp. 1401-1405, Feb. 1995, Medical Sciences.
Engelhardt, John F., Ablation of E2A in Recombinant Adenoviruses Improves Transgene Persistence and Decreases Inflammatory Response in Mouse Liver, Proc, Natl. Acad. Sci. USA, vol. 91, pp. 6196-6200, Jun. 1994, Medical Sciences.
Ilan, Yaron et al., Transient Immunosuppression With FK506 Permits Long-Term Expression of Therapeutic Genes Introduced Into the Liver Using Recombinant Adenoviruses in the Rat, Hepatology, pp. 949-956, 26(4), 1997, Chemical Abstracts Service, Columbus, Ohio.
Jenkins, Marc K., The Ups and Downs of T Cell Costimulation, Immunity, vol. 1, pp. 443-446, Sep., 1994, Cell Press.
Kay, Mark A. et al., Long-Term Hepatic Adenovirus-Mediated Gene Expression in Mice Following CTLA41g Administration, Nature Genetics, vol. 11, Oct. 1995, pp. 191-197.
Lenschow, Deborah J. et al., CD28/B7 System of T Cell Costimulation, Ann. Rev. Immunol., vol. 14, pp. 233-258 (1996).
Shen, Wel-Young et al., Combined Effect of Cyclosporine and Sirolimus on Improving the Longevity of Recombinant Adenovirus-Mediated Transgene Expression in the Retina, Arch Ophthalmol., vol. 119, Jul. 2001, pp. 1033-1043; American Medical Association.
Ziegler,.Robin J. et al., Correction of Enzymatic and Lysosomal Storage Defects in Fabry Mice by Adenovirus-Mediated Gene Transfer, Human Gene Therapy, vol. 10, pp. 1667-1682 (Jul. 1, 1999); Mary Ann Liebert, Inc.
Genzyme Corporation
Qian Celian
LandOfFree
Use of rapamycin to inhibit immune response and induce... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of rapamycin to inhibit immune response and induce..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of rapamycin to inhibit immune response and induce... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3602792